Technicals — It closed at HK$181.60, up 11.48%, flagged by both the HK hot and HK breakout screens. Price sits above the 20-day (HK$158.18), 50-day (HK$143.29) and 200-day (HK$121.23) in perfect bullish alignment, just 2.7% below the HK$186.60 high. The cost is RSI(14) at 76.0 and RSI(7) at 86.4, firmly overbought. Relative volume of 2.7x confirms a genuine volume breakout. ATR is HK$8.36. Both A- and H-shares gapped up on 8/4, with the H-shares spiking more than 14% intraday — short-term sentiment is already euphoric.
Fundamentals — First-half 2026 revenue reached RMB28.90B, up 38.93%, with net profit of RMB11.08B up 29.43% — the first time net profit has crossed RMB10B. Q2 alone brought RMB16.46B with growth accelerating to 47.71%, an acceleration rather than a fade. Full-year revenue guidance was lifted sharply from RMB51.3–53.0B to RMB58.5–60.5B, and continuing-operations growth guidance from 18–22% to 35–39%. Backlog stood at RMB66.43B at quarter end, up 25.2% — the substantive basis for the raise. The stock trades at 24.2x trailing earnings against 82.2% EPS growth.
News — WuXi AppTec released interim results and comprehensively raised full-year guidance on the evening of 8/3, igniting the entire CXO complex. Both A- and H-shares gapped up on 8/4, with the H-shares spiking over 14% intraday and CXO-heavy Stock Connect healthcare ETFs gaining more than 5% in a session. Peers moved with it: WuXi Bio +4.43%, Pharmaron +7.93%. The broader Hang Seng closed +0.48% back above 26,000 on 8/3 with southbound net buying of HK$11.03B, concentrated in healthcare and platforms — policy and flows both blowing the same direction for CXO.
The fundamental gear change is real: Q2 growth accelerating to 47.71%, backlog up 25.2%, and a single-shot guidance raise of more than RMB7B — a signal worth booking. But RSI(7) at 86.4 plus a 14% gap on 8/4 morning makes chasing terrible risk/reward. The HK$168–175 zone, the prior breakout shelf above the 20-day, is the rational entry, with a stop at HK$157 below the 20-day at HK$158.18 and a measured target of HK$205 above the 52-week high.
A RMB66.43B backlog up 25.2% provides genuine revenue visibility into the next two years, and Q2 acceleration to 47.71% shows global pharma R&D outsourcing demand is materially recovering. At 24.2x against 82.2% EPS growth, the valuation is still reasonable for the CXO leader.
- US biosecurity legislation remains a permanent tail risk for the sector
- At RSI 76, any good news landing can trigger profit-taking
- Consensus targets sit only 3.9% above spot; the near-term valuation cushion is spent
- 港股通 · Southbound net buying of HK$11.03B landed heavily in healthcare — mainland money recognized what this guidance was worth before local Hong Kong investors didOriginal ↗
- 华尔街共识 · 19 analysts average a HK$188.77 target, only 3.9% above spot, at a 1.11 rating near strong buy — the price has caught up to the targets and upward revisions look likely
